In a previous work, we showed that CSF-470 vaccine plus bacillus Calmette-Guerin (BCG) and granulocyte macrophage colony-stimulating factor (GM-CSF) as adjuvants resulted in a significant benefit in the distant metastasis-free survival when comparing vaccinated vs. IFN-α2b-treated high-risk cutaneous melanoma patients in a Phase II study. Immune monitoring demonstrated an increase in anti-tumor...

Human mucin 1 (MUC1) is a target for immunotherapy. The major problem associated with MUC1‑based cancer vaccines is the weakness of the immunogenicity of MUC1. The present study aimed to develop an efficient cancer vaccine through generating a recombinant fusion protein consisting of MUC1 and maltose‑binding protein (MBP) by inserting seven tandem repeats encoding the human MUC1 gene into the p...

Tuberculosis (TB) remains one of the major causes of infectious morbidity and mortality globally, claiming millions of lives every year. Approximately one-third of the world’s population is estimated to be infected with Mycobacterium tuberculosis, giving rise to 9.4 million new cases of active TB disease each year [1]. The majority of the TB burden exists in 22 high-burden countries, but with i...

BACKGROUND Although the role of bacillus Calmette Guerin (BCG) vaccine in the prevention of leprosy was hypothesized as early as 1939, its level of protective effect remained controversial. AIM As a meta-analysis systematically combines the results from different studies, we summarize the protective effect of BCG vaccine in prevention of leprosy using meta-analytic procedures. METHODS Our s...

Mycobacterium tuberculosis infection claims approximately 2 million lives per year, and improved efficacy of the BCG vaccine remains a World Health Organization priority. Successful vaccination against M. tuberculosis requires the induction and maintenance of T cells. Targeting molecules that promote T-cell survival may therefore provide an alternative strategy to classic adjuvants. We show tha...

the only available vaccine against tuberculosis is bcg which has been found to protect children against disseminated tuberculosis and tuberculous meningitis. bcg is one of the safest vaccines being used, and osteitis is a rare complication of it. during a period of eight years, we had eleven cases of osteitis occuring in infants following bcg vaccination. eight cases were female. defect in immu...

the (bacille calmette-gue´rin) bcg is widely practiced in many countries in pediatric group and is a part of routine vaccination program at birth in ir. iran for prophylaxis against tuberculosis, but its efficacy is a matter of debate in different geographic and ethnic regions. adverse reactions induced by bcg vaccination ranges from bcg adenitis, osteitis, and cold abscess at vaccination site ...

Tuberculosis caused by Mycobacterium bovis in domestic livestock and wildlife is a significant problem in many countries worldwide. Wildlife reservoirs of tuberculosis confound programs for tuberculosis eradication from domestic livestock. Successful vaccination against tuberculosis in domestic animals or wildlife could contribute to tuberculosis eradication. Bacille Calmette-Guérin (BCG) has b...

Tuberculosis affects nine million individuals and kills almost two million people every year. The only vaccine available, Bacillus Calmette-Guerin (BCG), has been used since its inception in 1921. Although BCG induces host-protective T helper 1 (Th1) cell immune responses, which play a central role in host protection, its efficacy is unsatisfactory, suggesting that additional methods to enhance...

Bacillus Camette-Guérin (BCG) vaccine is the only licensed vaccine against tuberculosis, yet its protective efficacy is highly variable between different geographical regions. We hypothesized that exposure to nontuberculous mycobacteria attenuates BCG immunogenicity by inducing mycobacterial-specific regulatory T cells (Tregs). Gambian neonates were recruited at birth and randomized to receive ...